PharmaShots | Incisive News in 3 Shots

Subscribe Now

amolyt pharma

Amolyt Pharma’s Eneboparatide Receives the US FDA’s Fast Track Designation for Hypoparathyroidism

Amolyt Pharma’s Eneboparatide Receives the US FDA’s Fast Track Designation for Hypoparathyroidism

May 3, 2024

Amolyt Pharma to Initiate P-III Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism

Amolyt Pharma to Initiate P-III Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism

May 3, 2023

PharmaShots Interview: Amolyt Pharma's Thierry Abribat Shares Insight on AZP-3601 for Hypoparathyroidism

PharmaShots Interview: Amolyt Pharma's Thierry Abribat Shares Insight on AZP-3601 for Hypoparathyroidism

May 10, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us